News and Announcements
OncoSil Medical CE Mark Update
- Published October 13, 2015 1:32PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
12th October 2015, ASX Announcement
OnoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to provide the following update on its Conformité Européenne (CE) Mark application for the Company’s OncoSilTM localised radiation treatment for cancer.
As previously advised (ASX announcement, 9 September 2015), OncoSil Medical was granted a Fast Track review by the European regulator to assess its CE Mark application for OcoSilTM in pancreatic and primary liver cancer (HCC).
OncoSil Medical now advises that the Fast Track Face-To-Face review phase has been completed, and it now awaits the final outcome of the review as the Notified Body continues to its assessment over the coming weeks. The Compnay was pleased with the review meeting and anticipates that the Notified Body will make a decision in respect of the CE Mark for OncoSilTM in November.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
